The best investments are those where, opposite to popular opinion, one does not have to be the smartest person in the room. The best investments are ones where the odds of success are so far tilted to ones favor that even if so much can be wrong in one thesis, you still end up d

Hot Low Price Stocks To Invest In Right Now

(Editor’s note: There is much greater liquidity on the Frankfurt Stock Exchange under ticker Z01).

The Elevator Pitch

Zooplus (OTC:ZOPLY) (OTC:ZLPSF) is the leading online retailer of pet food and supplies in Europe. Generally, in a commoditized market such as selling pet food, the lowest cost provider with the best customer service has the “right to win”. We believe that Zooplus will be this winner, given its structural cost advantage versus its competitors (which we explore below). Additionally, customer satisfaction is extremely high, and we can clearly see customers’ appreciation for the company’s value proposition, as evidenced by the 94% sales retention rate. These unbeatable low prices and high customer satisfaction have led to a 31% annualized sales growth rate since 2010, while still possessing a long runway for continued expansion.

We believe the market is underestimating the long-term earnings power of the firm and consequently significantly undervaluing the company. For instance, the stock is currently trading at 0.9x 2016 sales while comparable acquisitions have taken place at 2-6x multiples. Additionally, we believe at maturity, the business will have normalized operating margins of 8-10%, implying a valuation of ~10x normalized EBIT.

RepliCel Life Sciences Inc. (OTCBB: REPCF) (TSX: RP.V) – could be changing the way we treat baldness and hair loss in the future.

A clinical-stage regenerative medicine company, RepliCel is developing a unique biologic product that harnesses a patient’s own cells to treat pattern baldness and thinning hair, as well as products for aging and sun-damaged skin, and chronic tendon degeneration. The company recently announced the successful completion of its first-in-human clinical study of autologous cell therapy for the treatment of Androgenetic Alopecia, commonly known as pattern baldness.

“The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”

We love how well developed the selling of Immersion shares has been. Rather than a sharp, v-shaped reversal — which may or may not follow through — we’ve seen a bowl-shaped transition from an uptrend to a downtrend. This ups the odds of downside follow-through, as there’s been no price “shock” to invite a sudden wave of buying.

Watsco’s current P/E of 24.5 is in the same ballpark as its competitor Lennox International (NYSE: LII ) (NYSE: LII ) (NYSE: LII ) , whose P/E is 23.8. Lennox is a manufacturer of HVAC equipment and components, and will also benefit from HVAC industry tailwinds.

Not to be outdone, rival Canadian oil pipeline giant Enbridge (NYSE:ENB) announced a transformational gas-focused deal of its own, agreeing to acquire U.S. pipeline company Spectra Energy (NYSE:SE) for $28 billion. That transaction will catapult Enbridge past TransCanada and create the largest energy infrastructure company in North America. Further, the deal will bolster Enbridge’s near-term capital project backlog to $20 billion, while enhancing its inventory of longer-term investment opportunities to $37 billion. This pipeline supports Enbridge’s view that it can increase its dividend by 10% to 12% annually through 2024.

Analysts at Jefferies initiated coverage on business process services provider Maximus Inc. (MMS) late on Thursday, giving the stock a bullish rating because it has several competitive advantages and should benefit from the Affordable Care Act (Obamacare).

The analysts rate MMS as “Buy” and see shares reaching $47. This price target suggests a 20% upside to the stock’s Thursday closing price of $39.14.

“MMS is a leading government outsourced contractor that produces consistently strong results,” Jefferies analyst David Styblo commented. “The company has several competitive advantages and is highly focused on health and human service projects. This positions MMS to enjoy multi-year growth from the ACA and other opportunities with limited risk. The company’s predictable business model, solid balance sheet, and EPS visibility into FY2014 also support a Buy and $47 PT.”

Maximus shares were inactive during pre-market trading on Friday. The stock is up 23.83% year-to-date.

Wacker Neuson (ETR:WAC) received a €40.00 ($47.62) price target from research analysts at Hauck & Aufhaeuser in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Hauck & Aufhaeuser’s price objective would i

The best investments are those where, opposite to popular opinion, one does not have to be the smartest person in the room. The best investments are ones where the odds of success are so far tilted to ones favor that even if so much can be wrong in one thesis, you still end up d

Starbucks will close all its company-owned coffee shops in the U.S.and its corporate offices during the afternoon of May 29 to conductracial-bias training foremployeesfollowing the arrest oftwo African-American men at one of its locations in Philadelphia last week.

The Stock Exchange is all about trading. Each week we do the following:

Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamental analysts